Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 9/20 | 0.56 |
| ▸ | FNTB | P49356 | 9/20 | 0.56 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.50 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.43 |
| ▸ | CNR1 | P21554 | 3/20 | 0.41 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.41 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.39 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.39 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.39 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7203867 | 0.85 | FNTA (0.49) | FNTAFNTBPGGT1BCYP19A1CNR1 | |
| SCHEMBL7210122 | 0.82 | FNTA (0.54) | FNTAFNTBPGGT1BCYP19A1CNR1 | |
| SCHEMBL7203407 | 0.81 | FNTA (0.55) | FNTAFNTBPGGT1BCYP1A2 | |
| SCHEMBL5164053 | 0.77 | FNTA (0.46) | FNTAFNTBPGGT1BCYP19A1CYP1A2 | |
| SCHEMBL6868055 | 0.76 | FNTA (0.63) | FNTAFNTBCYP19A1CNR1CYP1A2 | |
| SCHEMBL4156125 | 0.76 | FNTA (0.85) | FNTAFNTBCYP19A1CNR1CYP1A2 | |
| Water SCHEMBL7207857 | 0.74 | FNTA (0.67) | FNTAFNTBPGGT1B | |
| SCHEMBL6870078 | 0.74 | CYP19A1 (0.50) | FNTAFNTBCYP19A1CYP1A2CYP3A4 | |
| SCHEMBL4428705 | 0.73 | FNTA (0.56) | FNTAFNTBPGGT1BCYP1A2 | |
| SCHEMBL6870980 | 0.72 | FNTA (0.60) | FNTAFNTBCYP19A1CNR1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2155197-A2 | TREATMENT OF LYSOSOMAL STORAGE DISEASES | Link Medicine Corporation (US) | 2010-02-24 | — | — | EP | claimed |
| EP-1809265-A4 | METHODS FOR THE TREATMENT OF SYNUCLEINOPATHIES | BRIGHAM & WOMENS HOSPITAL (US) | 2009-06-17 | — | — | EP | claimed |
| WO-2008112525-A2 | TREATMENT OF LYSOSOMAL STORAGE DISEASES | LINK MEDICINE CORPORATION (US) | 2008-09-18 | — | — | WO | claimed |
| EP-1478773-B1 | METHODS FOR ASSESSING ACUTE MYELOID LEUKEMIA | ORTHO CLINICAL DIAGNOSTICS INC (US) | 2007-09-19 | — | — | EP | claimed |
| EP-1809265-A2 | METHODS FOR THE TREATMENT OF SYNUCLEINOPATHIES | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2007-07-25 | — | — | EP | claimed |
| EP-1767656-A2 | Methods for assessing and treating leukemia | Ortho-Clinical Diagnostics, Inc. (US) | 2007-03-28 | — | — | EP | claimed |
| US-20070048782-A1 | Methods for assessing and treating leukemia | VERIDEX, LLC | 2007-03-01 | — | — | US | claimed |
| WO-2005089504-A2 | METHODS FOR THE TREATMENT OF SYNUCLEINOPATHIES | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2005-09-29 | — | — | WO | claimed |
| EP-1502962-A2 | Methods for assessing and treating cancer | Veridex, LLC (US) | 2005-02-02 | — | — | EP | claimed |
| US-20040110792-A1 | Methods for assessing and treating leukemia | VERDIDEX, LLC | 2004-06-10 | — | — | US | claimed |
| EP-0970079-B1 | FARNESYL TRANSFERASE INHIBITING 1,8-ANNELATED QUINOLINONE DERIVATIVES SUBSTITUTED WITH N- OR C-LINKED IMIDAZOLES | JANSSEN PHARMACEUTICA NV (BE) | 2003-10-01 | — | — | EP | claimed |
| US-20020049327-A1 | Farnesyl transferase inhibiting 1,8-annelated quinolinone derivatives substituted with N- or C-linked imidazoles | VENET MARC GASTON (FR) | 2002-04-25 | — | — | US | claimed |
| US-6187786-B1 | ANTITUMOR AND ANTICARCINOGENIC AGENTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2001-02-13 | — | — | US | claimed |
| EP-0970079-A1 | FARNESYL TRANSFERASE INHIBITING 1,8-ANNELATED QUINOLINONE DERIVATIVES SUBSTITUTED WITH N- OR C-LINKED IMIDAZOLES | JANSSEN PHARMACEUTICA N.V. (BE) | 2000-01-12 | — | — | EP | claimed |
| WO-1998040383-A1 | FARNESYL TRANSFERASE INHIBITING 1,8-ANNELATED QUINOLINONE DERIVATIVES SUBSTITUTED WITH N- OR C-LINKED IMIDAZOLES | JANSSEN PHARMACEUTICA N.V. (BE) | 1998-09-17 | — | — | WO | claimed |
| US-12274711-B2 | Method of determining Acute Myeloid Leukemia response to treatment with farnesyltransferase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2025-04-15 | — | — | US | disclosed |
| US-20230270769-A1 | Method of Determining Acute Myeloid Leukemia Response to Treatment With Farnesyltransferase Inhibitors | JANSSEN DIAGNOSTICS, LLC | 2023-08-31 | — | — | US | disclosed |
| US-6187786-B1 | ANTITUMOR AND ANTICARCINOGENIC AGENTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2001-02-13 | — | — | US | disclosed |
| EP-0970079-A1 | FARNESYL TRANSFERASE INHIBITING 1,8-ANNELATED QUINOLINONE DERIVATIVES SUBSTITUTED WITH N- OR C-LINKED IMIDAZOLES | JANSSEN PHARMACEUTICA N.V. (BE) | 2000-01-12 | — | — | EP | disclosed |
| WO-1998040383-A1 | FARNESYL TRANSFERASE INHIBITING 1,8-ANNELATED QUINOLINONE DERIVATIVES SUBSTITUTED WITH N- OR C-LINKED IMIDAZOLES | JANSSEN PHARMACEUTICA N.V. (BE) | 1998-09-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020049327-A1 | Farnesyl transferase inhibiting 1,8-annelated quinolinone derivatives substituted with N- or C-linked imidazoles | HCCS, CYP7A1, DHCR7 | FNTA 4/4885FNTB 5/4885PGGT1B 142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.